{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["IDH1 mutation", "glioma", "immune", "immune checkpoint blockade therapy", "signature"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36159801", "DateCompleted": {"Year": "2022", "Month": "09", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "09"}], "Language": ["eng"], "ELocationID": ["1001381", "10.3389/fimmu.2022.1001381"], "Journal": {"ISSN": "1664-3224", "JournalIssue": {"Volume": "13", "PubDate": {"Year": "2022"}}, "Title": "Frontiers in immunology", "ISOAbbreviation": "Front Immunol"}, "ArticleTitle": "A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.", "Pagination": {"StartPage": "1001381", "MedlinePgn": "1001381"}, "Abstract": {"AbstractText": ["Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and immune scores of TCGA glioma tissues were determined using the ESTIMATE algorithm. Differentially expressed genes (DEGs), the protein-protein interaction(PPI) network, and least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were used to select hub genes associated with stroma and immune scores and the prognoses of patients and to construct the risk model. The practicability and specificity of the risk model in both IDH1mt and IDH1-wildtype (wtIDH1) gliomas in TCGA and CGGA were evaluated. Molecular mechanisms, immunological characteristics and benefits of immune checkpoint blockade therapy in glioma tissues with IDH1mt were analyzed using GSEA, immunohistochemical staining, CIBERSORT, and T-cell dysfunction and exclusion (TIDE) analysis. The overall survival rate for IDH1mt-glioma patients with high stroma/immune scores was lower than that for those with low stroma/immune scores. A total of 222 DEGs were identified in IDH1mt glioma tissues with high stroma/immune scores. Among them, 72 genes had interactions in the PPI network, while three genes, <i>HLA-DQA2</i>, <i>HOXA3</i>, and <i>SAA2</i>, were selected as hub genes and used to construct risk models classifying patients into high- and low-risk score groups, followed by LASSO and Cox regression analyses. This risk model showed prognostic value in IDH1mt glioma in both TCGA and CCGA; nevertheless, the model was not suitable for wtIDH1 glioma. The risk model may act as an independent prognostic factor for IDH1mt glioma. IDH1mt glioma tissues from patients with high-risk scores showed more infiltration of M1 and CD8 T cells than those from patients with low-risk scores. Moreover, TIDE analysis showed that immune checkpoint blockade(ICB) therapy was highly beneficial for IDH1mt patients with high-risk scores. The risk model showed specific potential to predict the prognosis of IDH1mt-glioma patients, as well as guide ICB, contributing to the diagnosis and therapy of IDH1mt-glioma patients."], "CopyrightInformation": "Copyright \u00a9 2022 Zeng, Hu, Ruan, Zhang, Lei, Yang, Peng, Pan and Chen."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Zeng", "ForeName": "Zhirui", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China."}], "LastName": "Hu", "ForeName": "Chujiao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Clinical Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Ruan", "ForeName": "Wanyuan", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Jinjuan", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Lei", "ForeName": "Shan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Yang", "ForeName": "Yushi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Clinical Medicine, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guiyang, China."}], "LastName": "Peng", "ForeName": "Pailan", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Bone and Joint Surgery, Gui Zhou Orthopedic Hospital, Guiyang, China."}], "LastName": "Pan", "ForeName": "Feng", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Transformation Engineering Research Center of Chronic Disease Diagnosis and Treatment, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang, China."}], "LastName": "Chen", "ForeName": "Tengxiang", "Initials": "T"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Immunol", "NlmUniqueID": "101560960", "ISSNLinking": "1664-3224"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Immune Checkpoint Inhibitors"}, {"RegistryNumber": "EC 1.1.1.41", "NameOfSubstance": "Isocitrate Dehydrogenase"}, {"RegistryNumber": "EC 1.1.1.42.", "NameOfSubstance": "IDH1 protein, human"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Glioma"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Immune Checkpoint Inhibitors"}, {"QualifierName": ["genetics"], "DescriptorName": "Isocitrate Dehydrogenase"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": [], "DescriptorName": "Prognosis"}], "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. . Glioma targeted therapy: Insight into future of molecular approaches. Mol Cancer (2022) 21:39. doi:\u00a010.1186/s12943-022-01513-z", "ArticleIdList": ["10.1186/s12943-022-01513-z", "PMC8822752", "35135556"]}, {"Citation": "Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev (2017) 40:1\u201314. doi:\u00a010.1007/s10143-016-0709-8", "ArticleIdList": ["10.1007/s10143-016-0709-8", "27085859"]}, {"Citation": "Poff A, Koutnik AP, Egan KM, Sahebjam S, D\u2019Agostino D, Kumar NB. Targeting the warburg effect for cancer treatment: Ketogenic diets for management of glioma. Semin Cancer Biol (2019) 56:135\u201348. doi:\u00a010.1016/j.semcancer.2017.12.011", "ArticleIdList": ["10.1016/j.semcancer.2017.12.011", "PMC6927557", "29294371"]}, {"Citation": "Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol (2018) 51:50\u20138. doi:\u00a010.1016/j.semcancer.2017.11.010", "ArticleIdList": ["10.1016/j.semcancer.2017.11.010", "29170066"]}, {"Citation": "Huang LE. Friend or foe-IDH1 mutations in glioma 10 years on. Carcinogenesis (2019) 40:1299\u2013307. doi:\u00a010.1093/carcin/bgz134", "ArticleIdList": ["10.1093/carcin/bgz134", "PMC6875900", "31504231"]}, {"Citation": "Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives. J Blood Med (2016) 7:171\u201380. doi:\u00a010.2147/JBM.S70716", "ArticleIdList": ["10.2147/JBM.S70716", "PMC5015873", "27621679"]}, {"Citation": "Li Y, Shan X, Wu Z, Wang Y, Ling M, Fan X. IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. Seizure (2018) 55:76\u201382. doi:\u00a010.1016/j.seizure.2018.01.011", "ArticleIdList": ["10.1016/j.seizure.2018.01.011", "29414139"]}, {"Citation": "Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol (2021) 18:645\u201361. doi:\u00a010.1038/s41571-021-00521-0", "ArticleIdList": ["10.1038/s41571-021-00521-0", "34131315"]}, {"Citation": "Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell (2018) 173:530. doi:\u00a010.1016/j.cell.2018.03.059", "ArticleIdList": ["10.1016/j.cell.2018.03.059", "29625059"]}, {"Citation": "Wang Z, Lachmann A, Ma\u2019ayan A. Mining data and metadata from the gene expression omnibus. Biophys Rev (2019) 11:103\u201310. doi:\u00a010.1007/s12551-018-0490-8", "ArticleIdList": ["10.1007/s12551-018-0490-8", "PMC6381352", "30594974"]}, {"Citation": "Peng P, Cheng F, Dong Y, Chen Z, Zhang X, Guo D, et al. . High expression of TXNDC11 indicated unfavorable prognosis of glioma. Transl Cancer Res (2021) 10:5040\u201351. doi:\u00a010.21037/tcr-21-1326", "ArticleIdList": ["10.21037/tcr-21-1326", "PMC8799221", "35116356"]}, {"Citation": "Xu S, Wang Z, Ye J, Mei S, Zhang J. Identification of iron metabolism-related genes as prognostic indicators for lower-grade glioma. Front Oncol (2021) 11:729103. doi:\u00a010.3389/fonc.2021.729103", "ArticleIdList": ["10.3389/fonc.2021.729103", "PMC8458946", "34568059"]}, {"Citation": "Ren P, Wang J, Li L, Lin X, Wu G, Chen J, et al. . Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis. Bioengineered (2021) 12:3188\u2013200. doi:\u00a010.1080/21655979.2021.1943986", "ArticleIdList": ["10.1080/21655979.2021.1943986", "PMC8806787", "34238116"]}, {"Citation": "Park SY. Nomogram: An analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg (2018) 155:1793. doi:\u00a010.1016/j.jtcvs.2017.12.107", "ArticleIdList": ["10.1016/j.jtcvs.2017.12.107", "29370910"]}, {"Citation": "Zeng Z, Lei S, Wang J, Yang Y, Lan J, Tian Q, et al. . A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma. Bioengineered (2022) 13:12193\u2013210. doi:\u00a010.1080/21655979.2022.2073943", "ArticleIdList": ["10.1080/21655979.2022.2073943", "PMC9276011", "35549979"]}, {"Citation": "Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest (2017) 97:498\u2013518. doi:\u00a010.1038/labinvest.2017.19", "ArticleIdList": ["10.1038/labinvest.2017.19", "28287634"]}, {"Citation": "Sokratous G, Polyzoidis S, Ashkan K. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme. Hum Vaccin Immunother (2017) 13:2575\u201382. doi:\u00a010.1080/21645515.2017.1303582", "ArticleIdList": ["10.1080/21645515.2017.1303582", "PMC5703406", "28362548"]}, {"Citation": "Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics (2017) 14:284\u201397. doi:\u00a010.1007/s13311-017-0519-x", "ArticleIdList": ["10.1007/s13311-017-0519-x", "PMC5398991", "28281173"]}, {"Citation": "Gonzalez N, Asad AS, G\u00f3mez Escalante J, Pe\u00f1a Agudelo JA, Nicola Candia AJ, Garc\u00eda Fallit M, et al. . Potential of IDH mutations as immunotherapeutic targets in gliomas: A review and meta-analysis. Expert Opin Ther Targets (2021) 25:1045\u201360. doi:\u00a010.1080/14728222.2021.2017422", "ArticleIdList": ["10.1080/14728222.2021.2017422", "34904924"]}, {"Citation": "Leca J, Fortin J, Mak TW. Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers. Curr Opin Biotechnol (2021) 68:181\u20135. doi:\u00a010.1016/j.copbio.2020.11.013", "ArticleIdList": ["10.1016/j.copbio.2020.11.013", "33360716"]}, {"Citation": "Luo H, Tao C, Long X, Zhu X, Huang K. Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma. Bioengineered (2021) 12:7765\u201379. doi:\u00a010.1080/21655979.2021.1985340", "ArticleIdList": ["10.1080/21655979.2021.1985340", "PMC8806968", "34617871"]}, {"Citation": "Feng S, Liu H, Dong X, Du P, Guo H, Pang Q. Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma. Bioengineered (2021) 12:9692\u2013708. doi:\u00a010.1080/21655979.2021.1985818", "ArticleIdList": ["10.1080/21655979.2021.1985818", "PMC8810042", "34696669"]}, {"Citation": "Doxiadis GG, Otting N, de Groot NG, Bontrop RE. Differential evolutionary MHC class II strategies in humans and rhesus macaques: relevance for biomedical studies. Immunol Rev (2001) 183:76\u201385. doi:\u00a010.1034/j.1600-065x.2001.1830106.x", "ArticleIdList": ["10.1034/j.1600-065x.2001.1830106.x", "11782248"]}, {"Citation": "Zhang R, Shen S, Wei Y, Zhu Y, Li Y, Chen J, et al. . A Large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in europeans with a trans-ethnic validation in asians. J Thorac Oncol (2022) 30:974\u201390. doi:\u00a010.1016/j.jtho.2022.04.011", "ArticleIdList": ["10.1016/j.jtho.2022.04.011", "PMC9512697", "35500836"]}, {"Citation": "Kameda Y. Hoxa3 and signaling molecules involved in aortic arch patterning and remodeling. Cell Tissue Res (2009) 336(2):165\u201378. doi:\u00a010.1007/s00441-009-0760-7", "ArticleIdList": ["10.1007/s00441-009-0760-7", "19290546"]}, {"Citation": "Xia H, Liu Y, Wang Z, Zhang W, Qi M, Qi B, et al. . Long noncoding RNA HOTAIRM1 maintains tumorigenicity of glioblastoma stem-like cells through regulation of HOX gene expression. Neurotherapeutics (2020) 17(2):754\u201364. doi:\u00a010.1007/s13311-019-00799-0", "ArticleIdList": ["10.1007/s13311-019-00799-0", "PMC7283434", "31691127"]}, {"Citation": "Sack GH, Jr., Serum Amyloid A. (SAA) proteins. Subcell Biochem (2020) 94:421\u201336. doi:\u00a010.1007/978-3-030-41769-7_17", "ArticleIdList": ["10.1007/978-3-030-41769-7_17", "32189310"]}, {"Citation": "Han CY, Tang C, Guevara ME, Wei H, Wietecha T, Shao B, et al. . Serum amyloid a impairs the antiinflammatory properties of HDL. J Clin Invest (2016) 126(1):266\u201381. doi:\u00a010.1172/JCI83475", "ArticleIdList": ["10.1172/JCI83475", "PMC4701569", "26642365"]}, {"Citation": "Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, et al. . Serum amyloid a proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell (2020) 180(1):79\u201391.e16. doi:\u00a010.1016/j.cell.2019.11.026", "ArticleIdList": ["10.1016/j.cell.2019.11.026", "PMC7039443", "31866067"]}, {"Citation": "Adamski V, Hattermann K, Kubelt C, Cohrs G, Lucius R, Synowitz M, et al. . Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1. Oncogene (2020) 39(22):4421\u201335. doi:\u00a010.1038/s41388-020-1302-8", "ArticleIdList": ["10.1038/s41388-020-1302-8", "PMC7253351", "32346064"]}, {"Citation": "Wong-Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: Microbiome in cancer. Protein Cell (2021) 12:426\u201335. doi:\u00a010.1007/s13238-020-00813-8", "ArticleIdList": ["10.1007/s13238-020-00813-8", "PMC8106554", "33296049"]}, {"Citation": "Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell (2017) 31:326\u201341. doi:\u00a010.1016/j.ccell.2017.02.009", "ArticleIdList": ["10.1016/j.ccell.2017.02.009", "PMC5424263", "28292436"]}, {"Citation": "Ishikawa E, Miyazaki T, Takano S, Akutsu H. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy. Brain Tumor Pathol (2021) 38:149\u201355. doi:\u00a010.1007/s10014-021-00402-5", "ArticleIdList": ["10.1007/s10014-021-00402-5", "33977360"]}, {"Citation": "Lupo KB, Matosevic S. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma. J Hematol Oncol (2020) 13:76. doi:\u00a010.1186/s13045-020-00913-2", "ArticleIdList": ["10.1186/s13045-020-00913-2", "PMC7291472", "32532329"]}, {"Citation": "Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational immunotherapy for hepatocellular carcinoma: Radiotherapy, immune checkpoint blockade and beyond. Front Immunol (2020) 11:568759. doi:\u00a010.3389/fimmu.2020.568759", "ArticleIdList": ["10.3389/fimmu.2020.568759", "PMC7561368", "33117354"]}, {"Citation": "Isaacs J, Anders C, McArthur H, Force J. Biomarkers of immune checkpoint blockade response in triple-negative breast cancer. Curr Treat Options Oncol (2021) 22:38. doi:\u00a010.1007/s11864-021-00833-4", "ArticleIdList": ["10.1007/s11864-021-00833-4", "33743085"]}, {"Citation": "Kubli SP, Berger T, Araujo DV, Siu LL, Mak TW. Beyond immune checkpoint blockade: Emerging immunological strategies. Nat Rev Drug Discovery (2021) 20:899\u2013919. doi:\u00a010.1038/s41573-021-00155-y", "ArticleIdList": ["10.1038/s41573-021-00155-y", "33686237"]}, {"Citation": "Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: \u201cBeyond the T cell\u201d. J Immunother Cancer (2021) 9:e001460. doi:\u00a010.1136/jitc-2020-001460", "ArticleIdList": ["10.1136/jitc-2020-001460", "PMC7817791", "33468555"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "23"}, {"Year": "2022", "Month": "8", "Day": "8"}, {"Year": "2022", "Month": "9", "Day": "26", "Hour": "17", "Minute": "40"}, {"Year": "2022", "Month": "9", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["36159801", "PMC9500319", "10.3389/fimmu.2022.1001381"]}}], "PubmedBookArticle": []}